Logo
Logo

About Levetiracetam API

Product
  • Therapeutic CategoryCentral Nervous System (CNS)

  • CAS Number

    102767-28-2

  • API Technology

    Synthetic

  • Dose Form

    Hard Gelatin Capsule/Tablet for Suspension

  • Dr Reddy's Development Status

    Available

  • Available Regulatory Filing

    USDMF, CEP Submitted, Brazil DMF, Canada DMF, Japan DMF, Korea DMF, China DMF

Mechanism of Action

The precise mechanism(s) by which levetiracetam exerts its antiepileptic effect is unknown. The antiepileptic activity of levetiracetam was assessed in a number of animal models of epileptic seizures. Levetiracetam did not inhibit single seizures induced by maximal stimulation with electrical current or different chemoconvulsants and showed only minimal activity in submaximal stimulation and in threshold tests. Protection was observed, however, against secondarily generalized activity from focal seizures induced by pilocarpine and kainic acid, two chemoconvulsants that induce seizures that mimic some features of human complex partial seizures with secondary generalization. Levetiracetam also displayed inhibitory properties in the kindling model in rats, another model of human complex partial seizures, both during kindling development and in the fully kindled state. The predictive value of these animal models for specific types of human epilepsy is uncertain.

Indication

SPRITAM is indicated for adjunctive therapy in the treatment of: 

  • Partial onset seizures in patients with epilepsy 4 years of age and older weighing more than 20 kg
  • Myoclonic seizures in patients 12 years of age and older with juvenile myoclonic epilepsy
  • Primary generalized tonic-clonic seizures in patients 6 years of age and older with idiopathic generalized epilepsy

Related APIs

Atomoxetine Hydrochloride

Central Nervous System (CNS)

arrow

Benztropine Mesylate

Central Nervous System (CNS)

arrow

Dimethyl Fumarate

Central Nervous System (CNS)

arrow

Edaravone

Central Nervous System (CNS)

arrow

Eslicarbazepine Acetate

Central Nervous System (CNS)

arrow

Eszopiclone

Central Nervous System (CNS)

arrow

Levetiracetam

Central Nervous System (CNS)

arrow

Lumateperone Tosylate

Central Nervous System (CNS)

arrow

Lurasidone Hydrochloride

Central Nervous System (CNS)

arrow

Memantine Hydrochloride

Central Nervous System (CNS)

arrow

Pregabalin

Central Nervous System (CNS)

arrow

Rimegepant

Central Nervous System (CNS)

arrow

Risperidone

Central Nervous System (CNS)

arrow

Rivastigmine Hydrogen Tartrate

Central Nervous System (CNS)

arrow

Ropinirole Hydrochloride

Central Nervous System (CNS)

arrow

Sugammadex Sodium

Central Nervous System (CNS)

arrow

Tizanidine Hydrochloride

Central Nervous System (CNS)

arrow

Xanomeline

Central Nervous System (CNS)

arrow

Fluoxetine

Central Nervous System (CNS)

arrow

Quetiapine Fumarate

Central Nervous System (CNS)

arrow

Apremilast (form B)

Central Nervous System (CNS)

arrow

Donepezil Hydrochloride

Central Nervous System (CNS)

arrow

Siponimod Hemifumarate

Central Nervous System (CNS)

arrow

Ziprasidone Hydrochloride Anhydrous

Central Nervous System (CNS)

arrow

Request for Quotation

Get in touch with us by filling out the form below. Our team will reach out to you shortly!

Phone

Related Resources

Enhancing Supply Chain Security for Levetiracetam API

Enhancing Supply Chain Security for Levetiracetam API

Authors: AVT Reddy, Head - API Supply Chain; B Shivakumar, Product Manager - API

December, 2019

In this article we look at the factors, which can make an impact to ensure a reliable supply chain. Levetiracetam, one of the key APIs in our portfolios, is a model API, which shows how a diligent backward integration together with flexible capacities can enhance the security of the supply chain.

A brief background: Since 2017, the Chinese Government enforced environmental laws and regulations1) across the country to clean up air, water and upgrade its production efficiency. These regulations impacted numerous Key Starting Material suppliers resulting best case in a multifold price increase and worst case in a supply shortage. Our team at Dr Reddy’s implemented a diligent concept to tackle this situation in record time. The following 3 factors showed:

  1. Localization of KSM – Dr. Reddy’s entered into a strategic tie-up with China vendors and Indian business partners to transfer the technology/Know-how of KSM to India. Additionally, Dr Reddy’s further improved the technology in order to make it more sustainable by minimising the waste generation and re-using the solvents/reagents. Instead of shipping the KSM all the way from China, a local supplier can deliver faster and more flexible.
  2. Backed up by an alternative source – to further strengthen the supply chain, Dr. Reddy’s established another source for KSM in India. Following the same optimization principals as, mentioned above supplier has been qualified with approvals from global regulatory authorities including the USFDA and EDQM- in a record four months’ time.
  3. Scaling manufacturing capacities – To meet the increasing demand and to address the shortage, Dr. Reddy’s expanded the manufacturing capacity for Levetiracetam. The higher capacity ensures fastest turnaround times. Our process engineering team have developed crystallization processes and size reduction operations to meet customized physico-chemical properties  such as, but not limited to, particle size, bulk density (tapped /untapped) .

Within three to four months our OTIF (on time and in full) performance increased to 100 % and so did customer satisfaction. Today, Dr Reddy’s has achieved a competitive position in supporting the global Levetiracetam API demands.

 

Explore our Levetiracetam offering by clicking on the link below:

https://api.drreddys.com/product/levetiracetam

 

Reference

1) http://www.gov.cn/zhengce/content/2016-11/21/content_5135510.htm

FAQs

What is main purpose of using the levetiracetam API ?
  • A novel antiepileptic drug used in the treatment of partial seizures, myoclonic seizures, and tonic-clonic seizures.

What is the safety guide for levetiracetam API ?
  • 1000 mg once a day. Your doctor may adjust your dose as needed. However, the dose is usually not more than 3000 mg per day.

What is the process available for ordering levetiracetam API ?

Disclaimer

No information on this website, including any reference to any product or service constitutes an offer for sale or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, in certain cases, at Dr. Reddy's sole discretion, and subject to local legal requirement, the research quantities of such products may be offered for the purpose of regulatory submissions under Section 107A of the Indian Patent Act (Bolar exemption), wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the product or service including, patent scenario in their respective markets and will be responsible for all patent related liabilities Dr. Reddy's disclaims all warranties, express or implied, including but not limited to warranties of merchantability, fitness for a particular purpose and non-infringement.

Disclaimer: Products under patent(s) are offered only for R&D purposes U/S 107A of the Patent Act (Bolar Exemption) and not for commercial sale.